Toggle light / dark theme

Building the Future of Global Health: Big Tech’s Big Ideas

Ira Pastor, ideaXme longevity and aging ambassador and founder of Bioquark interviews Luba Greenwood J.D., Strategic Business Development and Corporate Ventures, Verily (Google Life Sciences), Board Member Mass Bio and Brooklyn ImmunoTherapeutics LLC.

Note: Following this interview, Verily announced a major set of collaborations with big pharma companies, further executing on its strategy in healthcare. Breaking news: https://www.cnbc.com/2019/05/20/alphabet-verily-doing-clinic…T4eLzIucEI

Ira Pastor comments:

In 2019 we have surpassed $7 trillion in total annual healthcare expenditures around the globe. As part of that $7 trillion, we’re now spending close to a $1 trillion a year on pharmaceutical products, $350 billion on medical devices, $200 billion on new Life Sciences R&D. Equally fascinating to note are the names of organizations becoming involved in this space in 2019.

From a U.S. centric perspective, 15 years ago when evaluting.
Healthcare Clinic, the first thing that would come to mind would be Kaiser Permanente; not Apple;
Medical Devices, Baxter or Medtronic; not Amazon would come to mind.
Pharmaceuticals, you would think Merck, Pfizer, Novartis, etc.; Not Google / Alphabet Inc. and their Calico longevity drug development initiatives.

Yet in the last couple years alone, these big tech companies have all made major strategic moves into health care, with the goal of using their Silicon Valley-honed skills (and major piles of cash) to try and disrupt the industry with various “moon shot” thinking, and the interests of these companies are really quite diverse from their core businesses.

Developing a Biotechnology Startup in the Rejuvenation Field

Alongside our Ending Age-related Diseases 2019 annual conference, we are proud to announce the launch of a special pre-conference biotech workshop led by Dr. Kelsey Moody, CEO of Ichor Therapeutics, a successful and rapidly growing rejuvenation biotechnology company.

This joint event between the Life Extension Advocacy Foundation and Ichor Therapeutics is an essential workshop where you will learn about the fundamentals of launching and growing a successful biotechnology company with an emphasis on the nuances specific to the emerging rejuvenation biotechnology industry.

Read more

Nutrient-Rich Diets May Lead to Dysbiosis and Age-Related Diseases

The role that the gut microbiome plays in aging is increasingly being appreciated in the research world as more evidence arrives to support it. A new publication reviews the various supporting evidence and takes a look at the gut microbiome in the context of nutrient-rich diets and how they facilitate the progression of dysbiosis and disease [1].

What is the microbiome?

The microbiome is the varied community of bacteria, archaea, eukarya, and viruses that inhabit our guts. The four bacterial phyla of Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria comprise 98% of the intestinal microbiome.

Read more

Luba Greenwood, J.D., Head of Strategic Business Development and Corporate Ventures at Verily (formerly Google Life Sciences) — ideaXme show — Ira Pastor

Natural “Fasting” Molecule Exerts Anti-Aging Effects to Protect Vascular System

A molecule produced by the body during fasting or calorie restriction has anti-aging effects on the vascular system, which could reduce the occurrence and severity of human diseases related to blood vessels, such as cardiovascular disease, according to a study led by Georgia State University.

“As people become older, they are more susceptible to disease, like cancer, cardiovascular disease and Alzheimer’s disease,” said Dr. Ming-Hui Zou, senior author of the study. “Age is the most important so-called risk factor for human disease. How to actually delay aging is a major pathway to reducing the incidence and severity of human disease.

Read more

/* */